In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct clinical trials in Australia has significantly…
https://etira.life/wp-content/uploads/2025/07/australia-rd-savings-etira.jpg14501530Carlton Hoythttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngCarlton Hoyt2025-07-16 08:27:302025-07-16 08:27:56Etira CEO Featured In Clinical Leader for R&D Efficiency
Innovative cancer therapy demonstrates favorable safety profile —
Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that the first patient has been…
Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South…
Chicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…
https://etira.life/wp-content/uploads/2025/04/AACR-2025-graphic-2K-e1746033763417.jpg10171083Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2025-04-30 11:25:242025-04-30 12:09:39Research on Etira drugs win awards at AACR 2025
Chicago, IL - April 23, 2025:
Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…
https://etira.life/wp-content/uploads/2025/04/Unknown.png14001266Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2025-04-24 14:25:482025-04-29 11:04:51Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
Adelaide, Australia – March 17, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research…
https://etira.life/wp-content/uploads/2025/03/image.png6821096Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2025-03-17 11:03:202025-03-17 11:03:20Second site activated for ERX-315 trial
Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase…
Dallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…
https://etira.life/wp-content/uploads/2024/12/image.png566658Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-12-02 10:06:322024-12-03 11:33:29Dr. Raj appointed as Etira Chief Medical Officer
Sydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia.…
Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath,…
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Etira CEO Featured In Clinical Leader for R&D Efficiency
NewsProgress in ERX-315 Phase 1 Clinical Trial
NewsEtira Expands Clinical Trial Sites
NewsResearch on Etira drugs win awards at AACR 2025
NewsPreclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
NewsSecond site activated for ERX-315 trial
NewsERX-315 Phase 1 Clinical Trial Update
NewsDr. Raj appointed as Etira Chief Medical Officer
NewsFirst patient dosed in ERX-315-101 Clinical Trial
NewsDrs. Jenkins and Stebbing join Etira Board
News